Managing Director & Senior Partner
John Gooch is the Regional Health Care lead for Europe, Middle East, South America, and Africa (EMESA) at Boston Consulting Group. He joined BCG in London in 1996 and has also spent time working in the New York and Paris offices.
John specializes in driving large programs focused on commercial and operational effectiveness, as well as setting up program management offices and systems.
He has broad experience in the global pharmaceutical sector, where his client engagements have covered R&D, operations, and commercial topics—particularly working with first-line leaders on both manufacturing and sales teams. He has also supported numerous post-merger integrations in the pharmaceutical industry.
John is also a member of BCG's GAMMA team, which creates competitive advantages for organizations by unleashing the power of signals hidden deep within large and complex data sets. BCG's GAMMA team conceptualizes, builds, and deploys advanced analytic solutions that can transform the trajectories of organizations in 12 to 24 months.
In addition, John has led work with some of the world's leading hospitals inside and outside the National Health Service, and he has significant experience in consumer health care.
Stakeholder support is crucial for ensuring that African vaccine-manufacturing companies can produce sufficient supply for the continent.
To deliver superior outcomes at scale, companies need to invest in ecosystems. Forging strong connections with patients and partners will be key.
Antimicrobial resistance is difficult to combat. This report gives a comprehensive assessment of vaccine R&D potential against pathogens with high levels of AMR.
European health care companies struggle with digital maturity. We have identified four reasons for this, and key success factors for addressing these challenges.
The pandemic has triggered a revolution in how health systems deliver care. It’s time to build on that momentum and make long-lasting improvements.
A new approach reveals that scale is the most important cost factor in biopharma, but one kind of scale stands out for its contribution to cost reduction.